Cleo Diagnostics (ASX:COV)
ASX announcement history & article coverage
Transparent by design.
Announcments by Cleo Diagnostics (ASX:COV) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
CLEO Enters Analytical Validation Phase
Cleo Diagnostics Commences Analytical Validation Phase Ahead of FDA Submission
Change in Director's Interest Notice
Cleansing Notice
Application for quotation of securities - COV
CLEO Establishes U.S. Reimbursement Pathway
Cleo Diagnostics establishes U.S. reimbursement pathway for ovarian cancer test ahead of FDA clearance
Quarterly activities and cashflow report
Cleo Diagnostics completes pivotal trial recruitment, advances manufacturing and FDA submission preparations
CLEO Commences Kit Manufacturing Ahead of FDA Submission
Cleo Diagnostics Starts Manufacturing Program with Bio-Techne Ahead of FDA Submission